Creative Biolabs has developed a novel T cell-based cancer immunotherapy system intended to directly help our clients with their projects including biomarker selection, TCR generation, TCR design and construction, TCR gene packaging and delivery, TCR preclinical test. We are leveraging our TCR development platform for rapid and high-quality identification of TCRs candidates.
On the way of cancer immunological therapy, altering the specificity of T cell receptor is one of the popular strategies to genetically modify T cells to enhance the tumor-killing activity of T cells. The first step in TCR gene therapy is to isolate a high-affinity T-cell clone for a defined target antigen. However, the isolation of these rare tumor-reactive T cell clones is often the rate-limiting step in this procedure and these clones often have low affinity for the target antigen. The majority of identified tumor-associated antigens are also expressed at low levels in normal tissues and mechanisms of tolerance induction are likely to affect the quality of T cell responses to such antigens. Until now, several approaches have been used to generate TCRs that are specific for other antigens that are expressed by a wider variety of tumor cell types.
One of them is to use T cells from transgenic mice that express human MHC. By the use of this method, TCR transgenic model is developed by Creative Biolabs to determine the magnitude of T cell tolerance to tumor-associated antigen. T cells are incubated with tumor cells from the patient and TCR genes are cloned from T cells that react to the tumor cells so that high-affinity TCRs for the target antigen are generated.
Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by E-mail and our team will get back to you as soon as possible.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE